GS-US-576-6220
12 Apr 2022
EVOKE-02
NCT05186974
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Gilead Sciences
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2022-02-01 |
Anticipated End Date | 2026-02-01 |
Hospital | Icon Cancer Centre Adelaide |
---|---|
Clinical Trial Coordinator | Sue Yeend |
sue.yeend@icon.team | |
Phone | 08 8292 2204 |
Principal Investigator | Dr Gonzalo Tapia Rico |
Recruitment Status | Recruiting |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Alison Richards |
Alison.Richards@sa.gov.au | |
Phone | 08 8206 4835 |
Principal Investigator | Professor Chris Karapetis |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs